[Pharmacokinetics and bioavailability of sustained-release tablets of matrine in dogs].
To study the pharmacokinetics and bioavailability of sustained-release tablets of Matrine in dogs. 6 dogs were randomly assigned to receive sustained-release tablets or commercial capsules 300 mg, then a crossover trial was conducted 1 week later. Plasma samples were taken at different time points and the plasma concentration of Oxymatrine and Matrine in dogs was determined by HPLC. The pharmacokinetic parameters of self-made sustained-release tablets versus those of its control preparation were as follows: Tmax: (6.17 +/- 2.04) (M), (3.25 +/- 0.61) (OM), (4.75 +/- 1.17) (M), (2.42 +/- 0.38) (OM) h; Cmax: (3.79 +/- 1.11) (M), (4.76 +/- 0.60) (OM), (5.35 +/- 0.72) (M), (7.04 +/- 0.47) (OM) microg/mL; AUC(0-->infinity): (45.15 +/- 11.77) (M), (32.38 +/- 4.60) (OM) and (44.71 +/- 5.52) (M), (29.11 +/- 4.41) (OM) microg x h/mL. The self-made sustained-release tablets and commercial capsules bioequivalent.